KDR and hepatocellular carcinoma: These data suggest that Klotho/VEGFR2/PAK1 signal inhibition with VEGFR2 inhibitor Axitinib, or anti-VEGFR2 blocking antibody, or PAK1 allosteric inhibitor IPA3 administration might be used as potential therapeutic interventions with progression and metastasis of HCC patients, which awaits further clinical investigations.